Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.
about
Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR ImagingModern brain tumor imagingEmerging Techniques in Brain Tumor Imaging: What Radiologists Need to KnowThrough the patient's eyes: an emphasis on patient-centered values in operative decision making in the management of malignant glioma.Perfusion MRI: the five most frequently asked clinical questions.Measurements of tumor vascular leakiness using DCE in brain tumors: clinical applications.Brain tumour mimics and chameleons.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging OptionsDefining the endpoints: how to measure the efficacy of drugs that are active against central nervous system metastases.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Current approaches to the treatment of metastatic brain tumours.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Delayed contrast extravasation MRI for depicting tumor and non-tumoral tissues in primary and metastatic brain tumors.Discriminating radiation necrosis from tumor progression in gliomas: a systematic review what is the best imaging modality?Semi-quantitative parameter analysis of DCE-MRI revisited: monte-carlo simulation, clinical comparisons, and clinical validation of measurement errors in patients with type 2 neurofibromatosis.Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies?Differentiating Radiation-Induced Necrosis from Recurrent Brain Tumor Using MR Perfusion and Spectroscopy: A Meta-AnalysisIntratumoral and peritumoral post-irradiation changes, but not viable tumor tissue, may respond to bevacizumab in previously irradiated meningiomasA pilot study to determine the timing and effect of bevacizumab on vascular normalization of metastatic brain tumors in breast cancer.MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.Current Clinical Brain Tumor ImagingComparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.Value of Dynamic Contrast-Enhanced MRI to Detect Local Tumor Recurrence in Primary Head and Neck Cancer Patients.Differentiating tumor recurrence from treatment necrosis: a review of neuro-oncologic imaging strategiesRadionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease.Pseudoprogression after glioma therapy: a comprehensive review.The role of neuropathology in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.The Use of MR Perfusion Imaging in the Evaluation of Tumor Progression in Gliomas.In Vivo DCE-MRI for the Discrimination Between Glioblastoma and Radiation Necrosis in Rats.Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI.Dynamic contrast-enhanced perfusion processing for neuroradiologists: model-dependent analysis may not be necessary for determining recurrent high-grade glioma versus treatment effect.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression.Prediction of pseudoprogression in patients with glioblastomas using the initial and final area under the curves ratio derived from dynamic contrast-enhanced T1-weighted perfusion MR imaging.Analysis of parametric histogram from dynamic contrast-enhanced MRI: application in evaluating brain tumor response to radiotherapy.The Initial Area Under the Curve Derived from Dynamic Contrast-Enhanced MRI Improves Prognosis Prediction in Glioblastoma with Unmethylated MGMT Promoter.Differentiation between Treatment-Induced Necrosis and Recurrent Tumors in Patients with Metastatic Brain Tumors: Comparison among 11C-Methionine-PET, FDG-PET, MR Permeability Imaging, and MRI-ADC-Preliminary Results.Which is the best advanced MR imaging protocol for predicting recurrent metastatic brain tumor following gamma-knife radiosurgery: focused on perfusion method.
P2860
Q26796223-321B8FE2-CCD5-4693-944B-237C697F8D3FQ27002344-8CA08CC2-D4AC-47F0-8628-F8F96CA1CA3DQ28068259-AB1A2075-052D-46ED-B366-F7B2CE65FC58Q30363967-68FC39DD-0394-45BE-A00F-0608E126285EQ30416198-0F418E21-102C-4903-ACFC-6B2F9BA5013BQ30653828-2021D1B0-2CD2-4AB9-BB49-D51D7BF10714Q30668865-CE2847F3-C261-4160-B9F8-A2F4F9854E01Q30907831-732B6400-B578-4F7A-A940-2DA2BF1DB6B6Q30938805-72BCC353-F2CC-4450-AE8E-8F008D3643FCQ30988706-90B1743D-C54D-4E48-8402-B6519189D4FAQ31158877-8AB2E15D-A73F-4CAD-BE4A-8DBD4D2325EDQ33616649-A78B2CC4-D3ED-444A-9F1F-09623B7EDDBEQ33696559-623DD33A-01FD-4E1B-A754-8DA7D1551D65Q33894461-153E1313-B372-42A8-8563-6C628301928FQ34517492-F01F512C-5C5E-41FB-9F1A-7B7194CB4B9AQ34560322-4E5E22CF-ABD5-4F59-9EF9-6E9671DB6570Q35110740-453BBFB4-C080-481F-92D1-C895E32644B9Q35879814-31537370-D460-4D58-81FF-EDCDF590FC4EQ35888150-9BD8C93B-49C4-418C-8611-ED0F59D60739Q35903183-ED2C4797-24F5-438C-B8B5-A57D7090FCC0Q36076814-D0E3CD9F-BCC5-4934-B91C-B4CE341683BEQ36097886-61CF0062-D599-424B-8BAD-A2DFF58DAC6CQ36367172-E6A672E1-B7BF-4F83-A3AD-D17D3C7DDF87Q36474762-B3917A76-F3AD-48D4-922F-8202DF30E21AQ36993641-014374F4-C062-4876-9C7F-19464ADAD782Q38074638-E0D33014-CDEA-4204-B750-266A64D3A6A7Q38092731-3DF8F644-D3BD-47F9-B52C-8FEC9151115AQ38094809-52A83B6E-173B-4E79-A4C4-E5723CA385DDQ38204718-69283C56-547E-4FEE-A263-2365EA20ABC3Q38773860-544A3822-1750-4F13-88BF-9152EEC0B32FQ38902139-54897E30-EE44-452D-BE85-8F7CAE57D211Q40120047-4436E2FA-BCE4-4F97-8BDF-126546DD47C2Q41698852-DC616D82-0495-4DC6-87C3-713F160CD6F6Q43376098-E65A40BE-6650-42A9-BC30-E13384D9A821Q43407297-2D21B400-E016-4002-8B4B-D29FA6001D17Q45179517-7515ED30-6E42-4B13-83E6-A036CF030F2BQ45840193-AE07E77B-ADD4-46E3-8C75-7846A9641A7FQ48234395-9CBD5CAA-51FD-4C09-8342-FBF85DB32D35Q48270232-8E62779E-354D-4679-8FAC-6DDDE305BBE4Q48374780-7C28C6E8-8F60-4EED-8EF0-3FC7CCA6A4B0
P2860
Differentiating treatment-induced necrosis from recurrent/progressive brain tumor using nonmodel-based semiquantitative indices derived from dynamic contrast-enhanced T1-weighted MR perfusion.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@ast
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@en
type
label
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@ast
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@en
prefLabel
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@ast
Differentiating treatment-indu ...... nced T1-weighted MR perfusion.
@en
P2093
P2860
P356
P1433
P1476
Differentiating treatment-indu ...... anced T1-weighted MR perfusion
@en
P2093
Abbas Babajani-Feremi
Ali Syed Arbab
David Hearshen
Jayant Narang
Lisa Scarpace
Mark L Rosenblum
Tom Mikkelsen
P2860
P304
P356
10.1093/NEUONC/NOR075
P50
P577
2011-07-29T00:00:00Z